|
|
Vaccine Detail
|
Recombinant Fowlpox-Mgp100 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-Mgp100 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007100
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: Pmel
- Description: This is for Melanoma Cancer. A vaccine consisting of a replication-defective recombinant fowlpox virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with recombinant fowlpox-mgp100 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth. (NCI04) (NCIT_C2805).
|
| Host Response |
|
|
| References |
NCIT_C2805: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805]
|
|
